Literature DB >> 24556619

Reply to comment on: Strong reduction of AGO2 expression in melanoma and cellular consequences.

D Völler1, A Bosserhoff1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24556619      PMCID: PMC4200103          DOI: 10.1038/bjc.2014.57

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Sir, We are grateful for the feedback regarding our article ‘Strong reduction of AGO2 expression in melanoma and cellular consequences' (Völler ). In this study, we discovered a melanoma-specific modulation of AGO2, a member of the miRNA-processing cascade. Moreover, we demonstrated that AGO2 reduction is a direct trigger for the deregulated miRNA pattern in melanoma. The reduced AGO2 protein amount was observed in melanoma cell lines as well as tissue samples of primary tumours and metastasis. Interestingly, AGO2 reduction was not detectable at mRNA expression level, which indicates a further processing of the AGO2 mRNA transcript in melanoma. Previous studies analysing the enzymes of the miRNA-processing cascade in cancer were either focused on the mRNA level (e.g., Sand ; Jafari ) or did not connect the deregulation with a disordered miRNA pattern (e.g., Ma ; Grund ; Jafarnejad ; Völler ). Therefore, we stated that ‘Deregulation of miRNA expression was observed in several types of cancer, but changes in the miRNA-processing enzymes have not been analyzed until today'. However, this statement would have to be focused on the enzyme AGO2 and analysis on protein level in melanoma. We apologize that the current statement is too general as the authors of the previous comment correctly stated.
  7 in total

1.  Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer.

Authors:  Michael Sand; Marina Skrygan; Dimitrios Georgas; Christoph Arenz; Thilo Gambichler; Daniel Sand; Peter Altmeyer; Falk G Bechara
Journal:  Mol Carcinog       Date:  2011-10-24       Impact factor: 4.784

2.  Rare Drosha splice variants are deficient in microRNA processing but do not affect general microRNA expression in cancer cells.

Authors:  Stefanie E Grund; Maria Polycarpou-Schwarz; Chonglin Luo; Stefan B Eichmüller; Sven Diederichs
Journal:  Neoplasia       Date:  2012-03       Impact factor: 5.715

Review 3.  MicroRNAs in malignant melanoma.

Authors:  Daniel Völler; Corinna Ott; Anja Bosserhoff
Journal:  Clin Biochem       Date:  2013-01-27       Impact factor: 3.281

4.  Expression levels of microRNA machinery components Drosha, Dicer and DGCR8 in human (AGS, HepG2, and KEYSE-30) cancer cell lines.

Authors:  Naser Jafari; Hadi Peeri Dogaheh; Shahab Bohlooli; Glenn G Oyong; Zohreh Shirzad; Fatemeh Alibeiki; Saeid Hosseini Asl; Seyed Jalal Zargar
Journal:  Int J Clin Exp Med       Date:  2013-04-12

5.  Up-regulated Dicer expression in patients with cutaneous melanoma.

Authors:  Zhihai Ma; Helen Swede; David Cassarino; Elizabeth Fleming; Andrew Fire; Soheil S Dadras
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

6.  Strong reduction of AGO2 expression in melanoma and cellular consequences.

Authors:  D Völler; J Reinders; G Meister; A-K Bosserhoff
Journal:  Br J Cancer       Date:  2013-10-29       Impact factor: 7.640

7.  Expression of the RNase III enzyme DROSHA is reduced during progression of human cutaneous melanoma.

Authors:  Seyed Mehdi Jafarnejad; Cecilia Sjoestroem; Magdalena Martinka; Gang Li
Journal:  Mod Pathol       Date:  2013-02-01       Impact factor: 7.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.